Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Job creation lowest on record among under-30s
-
9
NK troops disguised as 'indigenous' people in Far East for combat against Ukraine: report
-
10
Opposition leader awaits perjury trial ruling
Samsung Biologics’ 3rd plant gets business continuity certificate
By Lim Jeong-yeoPublished : May 19, 2020 - 15:27
Samsung Biologics, the world’s largest contract development and contract manufacturing organization for biologics drugs, said Tuesday that its third plant complies with international standards for business continuity management systems.
The plant is certified for compliance with ISO22301, a global standard set by the British Standard Institution, meaning the company’s business operations would experience minimal disruptions in the event of an accident or natural disaster.
Samsung Biologics had already acquired ISO22301 certification in April 2018 for individual features of its first and second plants. The additional accreditation covers its third plant, which began commercial operation in October 2018, as well as its bio-safety testing service lab and its small contract manufacturing organization manufacturing line.
Samsung Biologics’ third plant is the world’s largest single plant that has the throughput of 180,000 liters of biologics drug. It is equipped with N-1 perfusion technology, which can dramatically expedite the production rate.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
The plant is certified for compliance with ISO22301, a global standard set by the British Standard Institution, meaning the company’s business operations would experience minimal disruptions in the event of an accident or natural disaster.
Samsung Biologics had already acquired ISO22301 certification in April 2018 for individual features of its first and second plants. The additional accreditation covers its third plant, which began commercial operation in October 2018, as well as its bio-safety testing service lab and its small contract manufacturing organization manufacturing line.
Samsung Biologics’ third plant is the world’s largest single plant that has the throughput of 180,000 liters of biologics drug. It is equipped with N-1 perfusion technology, which can dramatically expedite the production rate.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
